The global attenuated vaccines market is on track to achieve significant growth, with revenues projected to rise from USD 5,068.2 million in 2024 to USD 9,693.9 million by 2034, reflecting a CAGR of 6.8% over the next decade. This growth is fueled by the increasing adoption of live, weakened vaccines for disease prevention, including vaccines for measles, mumps, rubella (MMR), chickenpox, and yellow fever, among others.
Attenuated vaccines, which consist of live viruses or bacteria that have been weakened to the point where they do not cause illness in healthy individuals, are highly effective in triggering the body’s immune response. These vaccines stimulate both antibody production and cellular immune defenses, providing robust protection against infections after just one or two doses. As a result, attenuated vaccines are widely recognized for their high efficacy in preventing diseases and improving public health.
While the benefits of these vaccines are significant, they are not recommended for individuals with weakened immune systems, as the live virus, even in its attenuated form, could pose a risk. Despite this limitation, the widespread use of attenuated vaccines in national immunization programs has been instrumental in reducing the burden of infectious diseases worldwide. Their ability to prevent high-risk diseases continues to contribute to global public health improvements.
The attenuated vaccines market presents a robust opportunity for vaccine manufacturers, healthcare providers, and public health organizations. With continued demand for highly effective vaccination options, particularly in disease eradication and prevention programs, the market is set to expand significantly in the coming years. As the importance of immunization continues to grow, the attenuated vaccines market is poised to remain a key component in the fight against infectious diseases.
Key Takeaways:
- Market Valuation: The global attenuated vaccines market is projected to grow from USD 5,068.2 million in 2024 to USD 9,693.9 million by 2034.
- Growth Momentum: The market is expected to expand at a CAGR of 6.8% between 2024 and 2034.
- Market Drivers: Rising demand for effective disease prevention, the success of vaccines like MMR and chickenpox, and the high protection rates from attenuated vaccines are key factors driving growth.
Overview of Attenuated Vaccines
Attenuated vaccines are created using live viruses or bacteria that have been weakened so they cannot cause disease in healthy individuals. These vaccines stimulate the immune system to recognize and combat the actual pathogens effectively. They are widely used to prevent diseases such as:
- Measles
- Mumps
- Rubella (MMR vaccine)
- Chickenpox
- Yellow fever
Advantages
- Strong Immune Response: Attenuated vaccines typically provoke a robust immune response, leading to high levels of antibody production and cellular immunity after just one or two doses.
- Long-lasting Immunity: The immunity conferred by these vaccines can be long-lasting, often providing lifelong protection against the diseases they target.
- Mimics Natural Infection: By closely resembling natural infections, these vaccines help train the immune system effectively.
Market Drivers
- Increased Awareness and Public Health Campaigns: Growing awareness about the effectiveness of vaccinations has led to higher uptake rates of attenuated vaccines.
- Rising Incidence of Infectious Diseases: The increasing prevalence of diseases preventable by vaccination drives demand for these products.
- Government Initiatives: Many governments are implementing vaccination programs that include attenuated vaccines as part of their public health strategies.
Competitive Landscape
Substantial investments are seen in the attenuated vaccines industry towards research and development in order to drive innovations. Another key strategic focus of these companies is to actively look for strategic partners to bolster their product portfolios and expand their global market presence.
Recent Industry Developments in Attenuated Vaccines Market
- In November 2023, Valneva SE, a specialty vaccine company received FDA approval for its IXCHIQ. IXCHIQ, is a single-dose, live-attenuated vaccine is prescribed for the prevention of chikungunya virus (CHIKV).
- In October 2023, Codagenix Inc., a clinical-stage synthetic biology company demonstrated the positive clinical data for CoviLiv COVID-19 vaccine candidate at the IDWeek 2023 annual meeting.
- In May 2023, Biofabri, a Spanish biopharmaceutical company collaborated with IAVI, an international nonprofit research organization and signed a agreement for development tuberculosis (TB) vaccine candidate MTBVAC
A Detailed Full Report – https://www.futuremarketinsights.com/reports/attenuated-vaccines-market
Key Players of Attenuated Vaccines Industry
- Merck & Co., Inc.
- GlaxoSmithKline plc
- Pfizer Inc.
- Sanofi
- Astellas Pharma
- Johnson & Johnson
- CSL Limited
- Serum Institute of India Pvt. Ltd.
- CARITAS
Key Segments of Attenuated Vaccines Industry
By Vaccines Type:
In terms of vaccines type, the industry is divided into monovalent attenuated vaccines, and multivalent attenuated vaccines.
By Indication:
In terms of indication, the industry is segregated into attenuated vaccines for influenza, attenuated vaccines for measles, mumps & rubella (MMR), attenuated vaccines for polio, attenuated vaccines for chickenpox, attenuated vaccines for shingles, attenuated vaccines for rotavirus and attenuated vaccines for other indications.
By Route of Administration:
In terms of route of administration, the industry is segregated into intramuscular attenuated vaccines administration, subcutaneous attenuated vaccines administration, oral attenuated vaccines administration, and intranasal attenuated vaccines administration
By Age Group:
In terms of age group, the industry is segregated into attenuated vaccines for pediatrics, attenuated vaccines for adolescents, attenuated vaccines for adults and attenuated vaccines for geriatric patients
By End-User:
The industry is classified by end user as attenuated vaccines for hospitals, attenuated vaccines for clinics and attenuated vaccines for other end users.
By Region:
Key countries of North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and Middle East and Africa (MEA) have been covered in the report.
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
